Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Intellia Therapeutics reported a quarterly loss of $0.92 per share, better than the Zacks Consensus Estimate of a loss of $1.02, and an improvement from a loss of $1.34 per share a year ago, resulting in an earnings surprise of +9.80% [1] - The company achieved revenues of $13.78 million for the quarter ended September 2025, which missed the Zacks Consensus Estimate by 12.35%, but showed growth from $9.11 million in the same quarter last year [2] - Intellia's stock has increased by approximately 16.4% year-to-date, outperforming the S&P 500's gain of 15.6% [3] Financial Performance - Over the last four quarters, Intellia has surpassed consensus EPS estimates four times and topped consensus revenue estimates three times [2] - The current consensus EPS estimate for the upcoming quarter is -$0.98 on revenues of $25.23 million, and for the current fiscal year, it is -$4.11 on revenues of $66.12 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which Intellia belongs, is currently ranked in the top 41% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Intellia's stock performance [5] Future Outlook - The sustainability of Intellia's stock price movement will largely depend on management's commentary during the earnings call and the subsequent revisions of earnings estimates [3][4] - The estimate revisions trend for Intellia was mixed prior to the earnings release, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6]